Novo Nordisk’s Post

We have delivered outstanding results again: 25% sales growth in H1 2024 🎉 🎉 🎉 If somebody asks you- do you know any 100 yrs old company growing at double digit YoY? Respond: yes, this is #NovoNordisk from #Denmark These stellar results would not be possible without our commitment to innovation and gender-balanced leadership. We have ca. 41% women at VP positions and 46% across all leadership positions! #genderbalance

Need help with your rare disease studies? See how YPrime supported this rare disease study by delivering our advanced, configurable #eCOA platform—transitioning from a previous vendor during the open-label extension (OLE) to drive clinical trial success. Read the case study here: https://hubs.ly/Q02L5XLn0 #RareDiseaseStudies, #YPrime, #eCOAPlatform

We are so proud YPrime’s eCOA has become a critical part for clinical trials in rare diseases like Pediatric Angelman Syndrome. YPrime’s ability to significantly enhance data quality, patient engagement, and trial efficiency by providing improved accuracy, reducing errors, and enabling remote data collection reinforces our promise of “Solving for Certainty” YPrime’s innovative eCOA solution lessens the burden on #patients and #caregivers while ensuring high-quality data collection—crucial in small patient populations. YPrime’s one of a kind comprehensive / flexibile technology is purpose built for the customization requirements specific to rare disease needs. Additionally, YPrime’s global reach facilitates consistent data collection across diverse sites, essential for all rare disease trials that often span multiple countries. These combined benefits make YPrime’s eCOA an invaluable tool in optimizing rare disease clinical trials, aimed at accelerating the development of new treatments for conditions like Pediatric Angelman Syndrome.

Taking steps towards co-design helps to not only build trust between patients and other stakeholders, but unlocks a host of benefits including optimizing of medicines and therapies, providing better data for regulatory decision-making, and raising awareness of rare disease. Learn more in our new whitepaper: https://bit.ly/3SRVGDA #AvalereHealth #RareDisease #PatientCoDesign #RareDiseaseMonth

As we turn the final pages of 2023, all of us at HRA Pharma Rare Diseases pause to reflect on a year marked by remarkable progress, breakthroughs, and moments that have defined our mission to transform healthcare in rare disease communities. In our Year-End Montage, we celebrate the milestones that have shaped our journey. This compilation is not just a series of memories; it's a narrative of resilience, innovation, and the relentless pursuit of making a difference in the lives of those affected by rare diseases. #YearInReview #2023Highlights #RareDiseases #HRAPharmaRareDiseasesImpact #HRAPharmaRareDiseases #Devotedtotherare

Taking steps towards co-design helps to not only build trust between patients and other stakeholders, but unlocks a host of benefits including optimizing of medicines and therapies, providing better data for regulatory decision-making, and raising awareness of rare disease. Learn more in our new whitepaper: https://bit.ly/3SRVGDA #AvalereHealth #RareDisease #PatientCoDesign #RareDiseaseDay

Coming up soon: February is Rare Disease Awareness Month. Rare Disease Awareness Month is a time for us to come together and share what it means to live with a rare disease, like scleroderma. Here are just two of many upcoming opportunities in February to participate and connect with other community members: ➡️ Virtual Meeting: The FDA is hosting a virtual public meeting for Rare Disease Day on March 1, 2024 to discuss topics like clinical trials, initiatives to advance medical product development, and more. Learn more: https://bit.ly/42ebGnu ➡️ Photo Contest: EURODIS is hosting a photo competition where anyone can submit a photo reflecting what it means to live with a rare disease. The deadline for submissions is January 31, 2024. Learn more: https://bit.ly/3HiPsHo Looking for more ways to be a part of spreading awareness and important discussions? Join us on social media to share stories and information, or connect with someone in your life and have a conversation. By spreading the word about rare disease like scleroderma and the urgent need for research, you can make a difference. #sayscleroderma #scleroderma #srfcure #rarediseasemonth #rarediseaseday #rarebutnotalone

The ADRIATIC trial for consolidation durvalumab in LS-SCLC represents one of the latest examples of IO moving into early-stage disease - my colleague Ian Love and I discuss these practice-changing results and their implications from #ASCO2024

Yesterday was a big day as our segment on generalized pustular psoriasis (#GPP) was featured on GMA3. This important coverage helps raise awareness for this disease and sheds light on the challenges faced by those impacted by it. Watch the full segment here: https://lnkd.in/eXUe_cDm

What does it take to see continued rare disease innovation in Europe?   While innovation in rare disease has brought transformative change to the lives of many patients, significant unmet need remains. In Europe today, a substantial number of patients with rare diseases lack an approved treatment option, experience shortcomings with current treatments or cannot access an approved treatment. Continued innovation in rare disease is essential to addressing remaining unmet needs.   To mark Rare Disease Day 2024, we will explore over the course of this week four critical elements to sustaining rare disease innovation in Europe:   1. Great science 2. Clear incentives 3. Supportive reimbursement policies 4. Strong community   These are outlined in our infographic here, building on work recently published by Dolon team members: https://bit.ly/42UC0Uf   #RareDiseaseDay2024 #RareDiseaseDay #RDD2024 #LightUpForRare #ShareYourColours #GetRareAware #RareDiseases #RareDiseaseAwareness #Dolon